https://european-biotechnology.net/wp-content/uploads/2025/09/Monte-Rosa-Therapeutics-team-buidling-e1758007966532-1030x580-1.jpg5801030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-09-16 07:33:452025-09-16 07:33:45Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal
https://european-biotechnology.net/wp-content/uploads/2025/09/UK-ABPI_1413460705_tg-e1757836939756.jpg477953Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-09-12 12:47:032025-09-12 12:47:03UK pharma lobby warns of crisis in British life sciences
https://european-biotechnology.net/wp-content/uploads/2025/09/NRG_1650536385_REE9VqiEAxf9lNiEm5SSpvIR9FyVo8Ko-e1757312244435.jpg480960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-09-08 07:00:342025-09-12 10:02:02NRG Therapeutics Ltd bags £50m in Series B financing
https://european-biotechnology.net/wp-content/uploads/2025/09/Blackmint-Studio_1390096280_U26uHM9LFjqU55doX7W4iHtws8esSYLR.jpg240429Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-09-07 04:53:222025-09-12 10:02:02Alt protein: EASAC sees immediate need for action
